Sarcoidosis is a granulomatous disease with an increased accumulation of T cells in lungs as a result of on-site proliferation and chemotaxis induced by chemokines. It has already been demonstrated that CCL3-5 levels were increased in HAL fluid of sarcoidosis patients. To analyze the expression of CCL3-5 chemokines by T-cell subtypes (CD4+, CD8+, Thl, Th2, Tel or Tc2) in the lungs of sarcoidosis patients, fifteen untreated sarcoidosis patients and eighteen control subjects were enrolled in this study. CD4+and CD8+ cells were isolated from HAL fluid by positive magnetic selection. The expression of CCL3-5 and other cytokines in CD4+and CD8+cells were measured by flow cytometry. The percentage ofCD4+ or CD8+ cells expressing CCL4 were significantly higher in sarcoidosis patients (22.3% and 58.1%) compared to those seen in healthy subjects (11.1% and 16.5%, P = 0.04 and P = 0.02, respectively). In addition, the expression of CCL3, CCL4 and CCL5 was significantly elevated in CD8+ cells (8.9%, 58.1% and 2.1%) compared to CD4+cells (2.1%,22.3% and 0.7%; P = 0.04, P = 0.009 and P = 0.04, respectively), whereas CCL4 was expressed by significantly more Tel than Thl cells in sarcoidosis patients (P = 0.006). Our study shows the possible role ofCD8+ cells and CD4+cells in recruiting T cells to the site of inflammation in sarcoidosis through the release of CCL4, either alone or together with ThllTel-associated cytokines.
to the site of inflammation (8) . It has been shown that CCL4 is a more potent chemoattractant for CD4+ than CD8+ cells, whereas CCL3/MIP-la are more effective in attracting CD8+ cells (9, 10) . CCL5 may influence the migration of T cells (especially CD45RO+ memory T cells) (11) , increase the proliferation ofT cells and stimulate cytotoxic T-cell responses. CCL3-5 chemokines may also indirectly regulate the inflammatory response by preferential recruitment of Thl cells as CCR receptor is more frequently found on activated Th 1 cells (3, 8) .
CCL4/MIP-l~levels were increased in BAL fluid of sarcoidosis patients compared to controls (3) . Capelli at al. also showed a correlation between levels of CCL4 and the number of CD4+ and CD8+ cells in BAL fluid (3) . Elevated levels of CCL3/ MIP-l a were only found in sarcoidosis patients, stages 2 or 3 (3) . BAL fluid CCL3 levels were found to be inversely correlated to diffusing capacity for carbon monoxide (DL eo) and the partial pressure of oxygen in blood (Pa0 2 ) in patients with fibrotic sarcoidosis (3) . CCL3 levels in BAL or blood were also increased in other studies (12, 13) . However, no differences were present in the Iida et al. study, in which only sarcoidosis patients with good prognosis were recruited (14) . Similarly, increased CCL5levels were reported in BAL fluid of sarcoidosis patients (11, (14) (15) (16) . Particularly high levels of CCL5 were observed in patients who require treatment and in those with active disease (16) . Additionally, CCL5 levels correlated with the number of lymphocytes and CD4+ cells in BAL fluid (14) (15) (16) . However, to date, it is not known whether T lymphocytes are a source of increased production of CCL3-5 chemokines in sarcoidosis. We only know, based on immunohistochemical and cell culture in vitro studies, that macrophages are rich producers of CCL3 and CCL5 in sarcoidosis (12, 17, 18) . CCL5 has been recently linked with increased expression of the Th 1 transcription factor T-bet in pulmonary sarcoidosis (19) .
The aim ofour study was to assess the production ofCCL3-5 chemokines by T cells and their subtypes (CD4+, CD8+, Thl, Th2, Tel or Tc2) in the lungs of sarcoidosis patients. Additionally, we sought to examine the relationship between the expression of CCL4 in T cells and levels of this chemokine in HAL.
MATERIALS AND METHODS

Subjects
The study protocol was approved by the ethics committee of the Silesian Medical University. All study participants provided written consent before enrolment in the study. Fifteen untreated sarcoidosis patients with a median age of 37 years (range 27-53 years) were recruited to the study. All patients fulfilled the criteria for sarcoidosis according to international guidelines (20) . The diagnosis was made when typical clinical manifestations, radiological findings and BAL cell profiles were supported by positive histological results from transbronchial biopsy (8 patients), mediastinoscopy (5 patients) and biopsy of peripheral lymph nodes (2 patients). Additionally, clinical and laboratory findings were negative for tuberculosis. The control group consisted of eighteen healthy subjects with a median age of 50 years (range 41-58 years) with no symptoms or history of any respiratory disease. The age did not show any significant differences between the sarcoidosis and control group. The characteristics of the subjects are shown in Table I .
Bronchoscopy and BAL
The tip of the bronchoscope was wedged into the orifice of a subsegmental bronchus of the middle lobe. Bronchoalveolar lavage (BAL) was performed by sequential installation and aspiration of8 separate aliquots of 25 mL of warm 0.9% normal saline. BAL fluid was centrifuged and the supernatant was frozen at -70°C until used for enzyme-linked immunosorbent assay (ELISA). A differential cell count was performed on cytospins ofBAL cells using May-Grunwald-Giemsa stain.
Isolation ofCD4+and CD8+ T cells from the BAL fluid
CD4+ and CD8+ cells were isolated from BAL fluid according to previously described procedures (21) . In brief, BAL cells were spun, washed and resuspended in the culture medium [RPMI-1640, 10% (vollvol) FCS, 2 mM l-glutamine, 100 IU/mL penicillin, and 100 mglmL streptomycin]. Macrophages were depleted by adhesion to plastic plates. The resulting non-adherent cells consisted mainly of lymphocytes, but variable amounts of dead cells, granulocytes, and epithelial cells were also present. Dead cells were eliminated with the Dead Cell Removal Kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
Table II. Combinations ofantibodies used in the study.
CD8+cells and then CD4+cells were isolated by positive selection using first MACS CD8+ MicroBeads and later MACS CD4+ MicroBeads (Miltenyi Biotec). The purity of isolated CD4+and CD8+ cells were consistently >95% as assessed by flow cytometry (FACS).
Flow cytometry
CD4+ and CD8+ cells were washed and stimulated for 6 h with phorbol 12-myristate 13-acetate (PMA; 10nglmL) and ionomycin (400nglmL) in the presence of brefeldin A (5mglmL). When a sufficient number of cells were obtained, part of them were incubated only in the presence of brefeldin A to check the expression of chemokines in unstimulated cells. Subsequently, the cells were washed twice in wash buffer, fixed in cold 4% formaldehyde, washed in PBS and frozen at -70°C for later use as previously described (21) . Cells were then thawed, washed, permeabilized, washed again and stained with a cocktail of antibodies (described in detail in Table II) or respective mouse isotype control antibodies for 30 min at room temperature in the dark (all antibodies originated from BD Pharmingen, Oxford, UK). After being washed twice, cells were resuspended in I% formaldehyde in PBS and analyzed within 24 h by four-colour flow cytometry (FACSCanto flow cytometer, BD Biosciences). CD4+ cells and CD8+cells expressing IFN-y, but not IL-4 were defined as Th 1 and TcI cells, respectively. Similarly, CD4+ cells and CD8+ cells positive for IL-4 but not for IFN-y were described as Th2 and Tc2, respectively.
ELISAfor CCL4/MIP-Jp
CCL4/MIP-I~expression in BAL fluid was measured by sandwich ELISA as recommended by the manufacturer (McKinley Place N.E., Minneapolis, USA). The lower limit of detection was 4 pg/ml.
Statistical analysis
Statistical analysis was performed with the use of software packages (GraphPad Prism 5.0; Statistica 9.0). 
Fluorochrome Antibodies
RESULTS
BAL cell characterization
BAL fluid recovery (P < 0.05), the number of isolated CD4+ (P < 0.001) and CD8+ cells (P < 0.0 I), as well as the percentage of lymphocytes in BAL fluid (P < 0.001) of sarcoidosis patients were significantly higher compared to control subjects. On the contrary, the percentage of macrophages demonstrated significant decrease in BAL fluid of sarcoidosis patients (P < 0.001). A full characteristic of BAL cells is provided in Table III .
The percentage of BAL fluid CD4+ or CD8+ cells, stimulated in vitro with PMA/ionomycin, expressing CCL4/MIP-IjJ or other cytokines
Representative examples of CCL4/MIP-I~e xpression together with IFN-y, IL-4 and TNF-a co-expression in CD8+ cells isolated from BAL fluid of sarcoidosis patients are shown in Fig. 1 . The percentage of CD4+or CD8+ cells expressing CCL4/ MIP-l~were significantly higher in sarcoidosis patients [22.3% (15-45 .8%) and 58.1% (35.1-65.7%), respectively] than in those seen in healthy subjects [11.1% (4.2-24.2%), P = 0.04 and 16.5% (12.4-57.6%), P = 0.02, respectively; Fig. 2 ]. In addition, CD8+ cells expressing CCL4/MIP-l~were present to a significantly greater extent compared to CD4+ cells expressing this chemokine within the sarcoidosis group (P = 0.009, Fig. 2 ).
CCL4 and IFN-y were co-expressed by a significantly higher percentage of CD4+ or CD8+ cells in sarcoidosis patients compared to healthy subjects [14.3% (6.6-26.7%) vs 6.7% (0.3-14.1%), P = 0.04 and 34.1% (17.5-47.8%) vs 3.1% (0.224.7%), P = 0.008, respectively; Fig. 3 ]. In addition, there was a significantly higher percentage of CD8+ cells co-expressing CCL4 and IFN-y compared to CD4+ cells co-expressing CCL4 and IFN-y in sarcoidosis patients (P = 0.03). In contrast, no significant difference was detected between the two studied groups in the percentage ofThl or Tel cells expressing CCL4. However, CCL4 was expressed by significantly more Tel than Th1 cells in sarcoidosis patients (P = 0.006; Fig. 4A ).
The percentage of CD4+ or CD8+ cells coexpressing CCL4 and TNF-a were significantly higher in sarcoidosis patients [14.6% (6.1-32.7%) and 32.2% (13.8-42.3%), respectively] than in healthy subjects [5.5% (0.513.6%), P = 0.03 and 1.4% (0.5-9.7%), P = 0.005, respectively]. There were low levels of CD4+or CD8+ cells co-expressing CCL4 and IL-4 and no differences were observed with respect to the percentages ofthose cells between the two studied groups. Similarly, the expression of CCL4 was low in Th2 and Tc2 cells and did not show any considerable difference between the sarcoidosis and control group.
The percentage of BAL fluid CD4+ or CD8+ cells, stimulated in vitro with PMA/ionomycin, expressing CCL3/MIP-l a or other cytokines
The percentage of CD4+or CD8+ cells expressing CCL3/MIP-1 a did not demonstrate any significant difference between the two studied groups. However, the expression of CCL3/MIP-1a was significantly elevated in CD8+ cells compared to CD4+ cells within the sarcoidosis group 
. Expression of CCL3-5 chemokines in CD8+ cells or Tel cells compared to CD4+ cells or Thl cells in sarcoidosis patients. A) Expression of CCL4 in BAL Tel cells vs BAL Thl cells in sarcoidosis; B) Expression of CCL3 in BAL CD8+ cells vs BAL CD4+ cells in sarcoidosis; C) Expression ofCCL5 in BAL CD8+ cells vs BAL CD4+ cells in sarcoidosis.
2.1% (0.7-5.4%), P = 0.04; Fig. 4B ]. There were no material differences in the co-expression of CCL3 with IFN-y, TNF-a, IL-4 or IL-IO in CD4+ or CD8+ cells between the sarcoidosis and control group.
The percentage of BAL fluid CD4+ or CD8+ cells, stimulated in vitro with PMA/ionomycin, expressing CCL51RANTES or other cytokines
No significant changes in the expression ofCCL5/ RANTES in CD4+ or CD8+ cells were observed between the two groups studied. However, the percentage ofCD4+cells expressing CCL5/RANTES showed considerable decrease compared to the percentage of CD8+cells expressing this chemokine in sarcoidosis patients [0.7% (0.4-0.8%) vs 2.1% (1.5-8.4%), P = 0.002; Fig. 4C ]. In addition, CCL5 and IL-4 were co-expressed by a significantly higher percentage of CD8+ cells in sarcoidosis patients compared to healthy subjects [0.4% (0.1-1%) vs 0% (0-0.2%), P = 0.02]. In contrast, there were no significant differences between the two studied groups in the percentage of CD8+ cells co-expressing CCL5 and IFN-y or the percentage of CD4+cells coexpressing CCL5 with IL-4, IL-IO or IFN-y.
The expression ofCCL3-5 chemokines in CD4+ cells isolatedfrom sarcoidosis patients and not stimulated with PMAlionomycin
The production of CCL4 by unstimulated CD4+ cells was very low and showed significant increase after PMA/ionomycin stimulation. On the contrary, the expression of CCL3 or CCL5 in CD4+ cells did not change after stimulation (Fig. 5) .
Levels ofCCL4IMIP-lfJ in the BALfluid
BAL fluid levels of CCL4/MIP-l~were significantly elevated in sarcoidosis patients compared to control subjects [0 pg/ml (0-12 pg/ml) vs 0 pg/ml (0-0 pg/ml), P = 0.03]. Levels of CCL4 in BAL fluid showed a weak but still significant correlation with the percentage of CD4+ cells expressing CCL4 (R = 0.37, P = 0.049), although not with the percentage of CD8+cells expressing CCL4. However, the levels ofCCL4 in BAL fluid correlated with the percentage of: Tc1 cells (R = 0.4, P = 0.03), CD8+ cells expressing TNF-a (R = 0.51, P = 0.005), CD8+ cells co-expressing TNF-a and CCL4 (R = 0.47, P = 0.02) and CD8+cells co-expressing TNF-a and IFN-y (R = 0.44, P = 0.02).
Correlations with BALfluid cells
The percentage of lymphocytes in BAL fluid showed a positive correlation with the percentage of CD8+ cells expressing CCL4 (R = 0.47, P = 0.01) and the levels of CCL4 in BAL fluid (R = 0.55, P = 0.002). In contrast, the percentage of eosinophils in BAL fluid correlated with: the percentage of Tc2 cells expressing CCL3 (R = 0.46, P = 0.02) and the percentage of CD4+ cells co-expressing IL-4 and CCL5 (R = 0.53, P = 0.04).
DISCUSSION
correlated with the percentage of CD4+ cells, Tc1 cells, CD8+ cells expressing TNF-a and CD8+ cells co-expressing TNF-a together with CCL4.
CCL3-5 are implicated in the pathogenesis of sarcoidosis because the levels of those chemokines were found to be elevated in BAL fluid of sarcoidosis patients (3, 11, (14) (15) (16) . Additionally, it is suggested, based on immunohistochemical and cell culture in vitro studies, that CCL3 and CCL5 are likely to be secreted by macrophages (12, 17, 18) . However, it was unclear whether BAL T cells are effective producers of CCL3-5 chemokine in sarcoidosis. The results of our study show that CCL4 is expressed in high amounts in T cells, especially in CD8+ cells. This may imply that CD8+ cells, and to a lesser extent CD4+ cells, may recruit new T cells to the site of inflammation in the lung of sarcoidosis patients. On the basis of the other studies, it seems probable that CCL4 attracts more CD4+ cells than CD8+ cells (9, 10) . The results of our study implicate a potentially new mechanism in the pathogenesis of sarcoidosis. The increased population of T cells, mostly CD4+ cells, present in the lung of sarcoidosis patients, are not only the result of T-cell proliferation at the site of the inflammation or migration of those cells caused by macrophages and other cells but also the result of T-cell chemotaxis induced by T cells. In this mechanism, activated CD8+ cells, and to a lesser degree CD4+ cells, would attract more T cells by producing large amounts of CCL4, especially CD4+ cells but also CD8+ cells, to the lung of sarcoidosis patients. A correlation analysis provided further support for the significance ofT cells as an important source of CCL4 because the percentage of CD4+ cells expressing CCL4 correlated with the levels of CCL4 in BAL fluid. While no significant correlation was found between the percentage of CD8+ cells expressing CCL4 and the levels of CCL4 in BAL fluid, the percentage of CD8+ cells expressing CCL4 correlated with the percentage of lymphocytes in BAL fluid. The levels of CCL4 in BAL fluid correlated with different subsets of CD8+ cells such as Tcl cells and CD8+ cells expressing TNF-a either alone or together with CCL4 or IFN-y.
Although we did not find that Tc1 cells or Th 1 cells of sarcoidosis patients produced more CCL4 compared to control subjects, we observed that CD8+ cells and CD4+ cells of sarcoidosis patients secreted To our knowledge, this is the first study showing that CD8+ and CD4+ cells isolated from BAL fluid of sarcoidosis patients release increased amounts of CCL4/MIP-l~either alone or together with IFN-y or TNF-a compared to control subjects. In addition, we observed that CD8+ cells compared to CD4+ cells of sarcoidosis patients were highly efficient producers of CCL3/MIP-l a, CCL4/MIP-l~, CCL5/ RANTES and CCL4 together with IFN-y. Similarly, the expression of CCL4 showed an increase in Tc1 cells in comparison with Thl cells in sarcoidosis patients. Finally, the levels of CCL4 in BAL fluid more CCL4 together with TcllThl cytokines (lFN-y and TNF-a) than in control subjects. Additionally, it is known from previous studies that CCL3-5 chemokines recruit Th 1/Tc1 cells preferentially (22) . It seems therefore that in sarcoidosis not only CCL4 attract more Tc11Th1 cells but also that CCL4 is to a greater extent co-expressed with Tc1/Th 1 cytokines in T cells. This new mechanism may also be partially responsible for the increased Thl cytokine pattern observed in the lungs of sarcoidosis patients without lung fibrosis.
Another new finding of our study is the importance of CD8+ cells for the production of CCL3-5 chemokines. We showed that CD8+ cells produced significantly more CCL3/MIP-la, CCL4/ MIP-l p, CCL5/RANTES and CCL4 together with IFN-y, compared to CD4+ cells of sarcoidosis patients. Additionally, when compared to Thl cells, Tc1 cells expressed significantly more CCL4 in the sarcoidosis group. These data indicate a possible role of CD8+ cells and Tc1 cells for the recruitment of T cells (especially CD4+cells and Thl cells) to the site of inflammation in the lung of sarcoidosis patients.
The significance ofthe increased co-expression of CCL5 and IL-4 in CD8+ cells in sarcoidosis patients compared to control subjects is uncertain because of the low percentage of such cells in HAL fluid and the absence of other relationships between CCL3-5 chemokines and Th2lTc2-associated cytokines in our study. However, this observation may require further studies as the association between CD8+cells, CCL5 and Th2lTc2-related cytokines may potentially be of importance, especially for the patients with lung fibrosis due to sarcoidosis.
In our study, we observed different patterns of expression of CCL4 versus CCL3 or CCL5 in unstimulated and stimulated T cells. The production of CCL3 or CCL5 was at the same level before and after stimulation, whereas the expression of CCL4 in unstimulated T cells was low but, similar to IFN-y and TNF-a ( Fig. 5) (21) , it increased many times after stimulation. Low basal expression ofCCL4 in T cells indicates that it may be difficult or even impossible to demonstrate an association between T cells and CCL4 with the use of immunohistochemistry in lung sections of sarcoidosis patients.
In summary, the results of our study show the possible role ofCD8+ cells and CD4+ cells in recruiting T cells to the site of inflammation in sarcoidosis through the release of CCL4 either alone or together with Th l/Tc l-associated cytokines. Additionally, our data suggest that CD8+ cells, rather than uCD4+ cells, are involved in the migration of T cells to the lung of sarcoidosis patients as CD8+ cells produced more CCL3-5 chemokines compared to CD4+ cells.
